Wedbush restated their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS - Free Report) in a research note published on Friday,Benzinga reports. They currently have a $4.00 price objective on the stock.
Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Gossamer Bio in a research note on Thursday, January 30th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $9.20.
Get Our Latest Research Report on GOSS
Gossamer Bio Stock Up 2.2 %
NASDAQ:GOSS traded up $0.03 during mid-day trading on Friday, hitting $1.42. 2,647,532 shares of the company's stock were exchanged, compared to its average volume of 1,563,638. Gossamer Bio has a one year low of $0.50 and a one year high of $1.55. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The business has a fifty day moving average price of $1.14 and a 200 day moving average price of $0.97. The company has a market cap of $321.78 million, a PE ratio of -4.44 and a beta of 1.86.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The business had revenue of $9.38 million for the quarter, compared to the consensus estimate of $7.02 million. Equities analysts predict that Gossamer Bio will post -0.28 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in GOSS. Graham Capital Management L.P. purchased a new position in shares of Gossamer Bio during the fourth quarter valued at approximately $32,000. US Bancorp DE purchased a new position in shares of Gossamer Bio during the third quarter valued at approximately $39,000. Fullcircle Wealth LLC purchased a new position in shares of Gossamer Bio during the fourth quarter valued at approximately $43,000. GSA Capital Partners LLP purchased a new position in shares of Gossamer Bio during the third quarter valued at approximately $67,000. Finally, Velan Capital Investment Management LP purchased a new stake in Gossamer Bio during the fourth quarter valued at approximately $68,000. 81.23% of the stock is owned by hedge funds and other institutional investors.
About Gossamer Bio
(
Get Free Report)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Further Reading
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
